IP Library Granted Patent US 10,407,664
Granted Patent B2
US 10,407,664 · App. 14/651,346 · Granted Sep 10, 2019

Three dimensional heterogeneously differentiated tissue culture

Inventors: Juergen Knoblich (Moedling, AT); Madeline A. Lancaster (Vienna, AT)
Assignee: IMBA—Institut Fur Molekulare Biotechnologie GMBH
C12N5/0619C12N5/0696C12N5/0697G01N33/5058C12N2501/33C12N2501/91C12N2506/02C12N2506/45C12N2513/00C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,407,664
App. No.
14/651,346
Granted
Sep 10, 2019
Kind
B2
Abstract

The present invention provides an artificial tissue culture comprising a heterogeneous population of cells of at least two different tissue sections, wherein said tissue sections are in a three dimensional structure, method of generating such a tissue and kits suitable for said method or maintain a three dimensional tissue culture.

Claims (22)

1. A three-dimensional neuronal tissue culture comprising outer radial glia cells; and said culture comprises a three dimensional matrix, wherein said three-dimensional matrix is a hydrogel.

2. The tissue culture according to claim 1 , wherein said tissue culture forms at least two layers.

3. The tissue culture according to claim 1 , wherein said tissue develops apical and dorsal tissue sections.

4. The tissue culture according to claim 1 , wherein said tissue is cerebral tissue.

5. The tissue culture according to claim 1 , wherein cells of said culture express one or more gene expression markers selected from forebrain markers BF1 and Six3, hindbrain markers Krox20 and Ils1.

6. The tissue culture according to claim 1 , wherein forebrain markers are expressed in increased amounts as compared to hindbrain markers in the tissue culture.

7. The tissue culture according to claim 1 , wherein cells of said culture express one or more gene expression markers selected from Otx1, Otx2, FoxG1, Auts2, Tuj1, Brn2, Satb2, Ctip2, calretinin.

8. The tissue culture according to claim 1 , wherein the three dimensional matrix comprises a collagen.

9. The tissue culture according to claim 1 , wherein said outer radial glia cells are in an outer or extra cortical subventricular zone and the tissue further comprises cells of a cortical inner fiber layer in an inner fiber layer.

10. A method of testing a candidate drug for neurological effects, comprising administering a candidate drug to an artificial culture according to claim 1 and determining an activity of interest of the cells of said culture and comparing said activity to an activity of cells to the culture without administering said candidate drug, wherein a differential activity indicates a neurological effect.

11. A method of obtaining a differentiated neural cell, the method comprising the step of providing an artificial culture according to claim 1 and isolating a differentiated neural cell of interest.

12. A method of generating a tissue culture according to claim 1 comprising:

a) providing a multicellular aggregation of pluripotent stem cells,

b) culturing said multicellular aggregation in neural induction medium thereby inducing the multicellular aggregation to differentiate to neuroepithelial cells,

c) culturing said differentiated neuroepithelial cells in drops of extracellular matrix derived from Engelbreth-Holm-Swarm sarcoma cells, thereby expanding said cells in a multicellular aggregation, and

d) culturing said expanded multicellular aggregation of cells from step c) in a suspension culture, thereby generating the tissue culture according to claim 1 .

13. The method of claim 12 , wherein said pluripotent cell is an induced pluripotent cell.

14. The method of claim 13 , wherein the induced pluripotent cell comprises a cell that has been isolated from a patient.

15. The method of claim 12 , further comprising decreasing or increasing the expression in a gene of interest in a cell at any stage during said method, wherein the method is used for investigating a developmental neurological tissue effect.

16. The method of claim 12 , further comprising administering a candidate agent to said cells at any stage during the method, wherein the method is used for screening a candidate therapeutic agent suitable for treating a developmental neurological tissue defect of interest.

17. The method of claim 16 , wherein administering a candidate agent to said cells at any stage during the method occurs at all stages during the method.

18. A method of obtaining a differentiated neural cell, the method comprising the step of generating an artificial tissue culture according to claim 12 and isolating a differentiated neural cell of interest.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: KNOBLICH, JUERGEN
To: INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBH
Reel/Frame 036377/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: LANCASTER, MADELINE A.
To: INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBH
Reel/Frame 036377/0509 →
Priority Claims (1)
EP 12196954 · Dec 13, 2012 · regional
Continuity (1)
Related Publication 20150330970A1 · Nov 19, 2015
Cited By (11)
US 12,241,090 US 12,258,584 US 12,281,334 US 12,297,457 US 12,379,372 US 12,414,967 US 12,421,500 US 12,428,622 US 12,497,597 US 12,534,709 US 12,600,943